Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Clinical trial NCT02870569 · COMPLETED
Trial details
- NCT number
- NCT02870569
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2018-07-02
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.